Single-Cell Network-Based Drug Repositioning for Discovery of Therapies against Anti-Tumour Necrosis Factor-Resistant Crohn’s Disease

Primary and secondary non-response affects approximately 50% of patients with Crohn’s disease treated with anti-tumour necrosis factor (TNF) monoclonal antibodies. To date, very little single cell research exists regarding drug repurposing in Crohn’s disease. We aimed to elucidate the cellular pheno...

Descripción completa

Detalles Bibliográficos
Autores principales: Kwak, Min Seob, Hwang, Chang-Il, Cha, Jae Myung, Jeon, Jung Won, Yoon, Jin Young, Park, Su Bee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10531326/
https://www.ncbi.nlm.nih.gov/pubmed/37762402
http://dx.doi.org/10.3390/ijms241814099

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10531326/
https://www.ncbi.nlm.nih.gov/pubmed/37762402
http://dx.doi.org/10.3390/ijms241814099

Ejemplares similares